Orforglipron vs injectable GLP-1 drugs: the oral pill explained

Semaglutide, tirzepatide and retatrutide are peptides: chains of 31 to 39 amino acids built on the structure of gut hormones and modified to last a week in the blood. Peptides are digested like any protein, which is why they are injected and why the one oral peptide on the market, Rybelsus, needs an absorption enhancer and a strict empty-stomach window to get a small fraction through the stomach wall.

Orforglipron is a non-peptide small molecule that binds the GLP-1 receptor at a different site and activates it. Lilly licensed it from Chugai and developed it as a once-daily tablet. Because it is not a protein, stomach acid and digestive enzymes do not destroy it, and it is absorbed like a conventional drug. That is the whole reason it exists: the same receptor as the injectables, reached without a needle and without the Rybelsus fasting rules.

Being a small molecule has a second consequence. Peptides are expensive and slow to manufacture at scale, which contributed to the semaglutide and tirzepatide shortages. A small molecule tablet is made the way most pills are made, in bulk, which is why Lilly has positioned it as a drug it can supply widely. It is also, for the purposes of this site, not a peptide at all, and it does not appear in the peptide dosage chart.

The injectables are weekly. Semaglutide (Wegovy) titrates from 0.25 to 2.4 mg over at least 16 weeks, tirzepatide (Zepbound) from 2.5 to as much as 15 mg in 4-week steps, and retatrutide's trials ran 1 or 2 mg up to 12 mg. Each is a subcutaneous injection into the abdomen, thigh or upper arm, stored in the fridge. The schedules are covered in the semaglutide and tirzepatide dosage charts.

Orforglipron is a tablet taken once daily, titrated upward in steps like the injectables so the gut can adapt. The Foundayo label sets the specific step doses; the structure is the same idea of a low start climbing over weeks to a maintenance dose. The label states it can be taken with or without food, which is the practical difference from Rybelsus, where the tablet has to be taken on an empty stomach with a small amount of water and nothing else for 30 minutes.

Daily dosing cuts both ways. A missed weekly injection has a 4 day grace window on the Zepbound label; a missed daily pill is a smaller event but happens more often. There is no reconstitution, no units calculation and no concentration confusion, which removes the whole category of dosing error that the insulin syringe units chart exists to prevent.

Orforglipron's phase 3 obesity trial reported average weight loss that was meaningful and clinically useful but lower than the injectable dual and triple agonists produced in their own trials. Tirzepatide reached about 20.9 percent in SURMOUNT-1 at 72 weeks and retatrutide's 2026 topline reported about 28 percent at 80 weeks. Orforglipron, acting on the GLP-1 receptor alone, sits closer to the single-agonist range than to those numbers. We are not quoting an exact figure here because the label and publication figures use different estimands and durations and a single number would mislead more than inform.

Cross-trial comparison is unreliable for the same reasons it is unreliable between retatrutide and tirzepatide: different populations, different durations, different handling of dropouts, different years. The only valid comparison is a head-to-head trial, and none has been run between orforglipron and any injectable for weight loss. The expectation from pharmacology is that a GLP-1-only agonist, oral or injected, produces less loss than a GLP-1 plus GIP agonist, and that expectation matches the trial pattern so far.

What orforglipron does have is a GLP-1 receptor profile similar to the injectables in its side effects: nausea, vomiting, constipation and diarrhea, worst during titration, with the same class warnings for pancreatitis, gallbladder disease and the rodent thyroid C-cell finding. The GLP-1 side effects article covers these, including the January 2026 MHRA alert on pancreatitis that applies to the class as a whole.

The clearest case is people who will not inject. Needle aversion keeps a meaningful share of eligible people off the injectables entirely, and for them a pill that produces solid weight loss beats an injection that produces more loss and never gets started. The second case is people whose situation makes refrigerated weekly pens impractical: frequent travel, no reliable fridge, or work patterns that make a fixed weekly injection day hard to keep.

A third case is people who did well on a GLP-1 injectable and want a maintenance option with less friction. There is no trial of orforglipron as a step-down from an injectable, so this is a use that will develop in practice rather than from evidence, and the GLP-1 microdosing article covers the broader lack of maintenance data in this class.

The weaker case is someone whose goal is maximum weight loss. The injectable dual and triple agonists produced more loss in their trials, and someone who tolerates injections and wants the largest effect has reason to prefer tirzepatide today or to watch retatrutide's filing timeline. The weight loss guide and the three-way comparison cover the injectable options.

Compounded semaglutide and tirzepatide grew during the branded shortages and persisted afterward through outsourcing facilities compounding from bulk powder. On April 30, 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, with the Federal Register notice on May 1 and the comment period closing June 29. As of October 2026 no final decision has been reported. If finalized, that route closes outside a declared shortage.

An approved pill with scalable manufacturing changes the demand side of the same market. Part of what pushed people to compounded and grey-market vials was price and availability of branded pens. A tablet that Lilly can make in volume and that needs no cold chain is positioned to undercut both problems, and every person who chooses a pill is one fewer buying a vial. Orforglipron cannot be compounded from bulk peptide powder because it is not a peptide, and the grey-market research vendors have no equivalent product to sell.

None of that eliminates the injectable market. Tirzepatide produces more loss, retatrutide may produce more still, and both remain in demand among people who want the maximum effect. What changes is the floor: the lowest-friction, most-available GLP-1 option is now an approved tablet rather than a compounded vial. Our buying guide tracks the compounding decision as it develops.

Orforglipron wins on convenience: a daily pill with no needle, no fridge, no food rules and no units math. The injectables win on effect size in their own trials, with tirzepatide and retatrutide well ahead of any GLP-1-only agonist. Semaglutide alone holds the cardiovascular outcomes data from SELECT, which orforglipron does not yet have, and tirzepatide has years of real-world use that a drug approved in April 2026 cannot match.

For someone deciding, the question is less which drug is best and more which drug they will actually take for a year or more. The withdrawal studies for every GLP-1 drug show regain after stopping, which makes adherence the variable that matters most. A pill someone takes beats an injection someone abandons. The compound pages for semaglutide, tirzepatide and retatrutide cover the injectable side in detail; orforglipron, not being a peptide, has no compound page here.